May 23 (Reuters) - Biohaven Pharmaceutical BHVN.N said on Monday a late-stage trial of its drug against spinocerebellar ataxia, a genetic neurological disease, failed to meet the main goal of the study. Spinocerebellar ataxia is a progressive disorder that causes symptoms such as uncoordinated movement, difficulties swallowing and muscle wasting. Biohaven said patients in both the drug and the placebo groups showed less-than-expected change in disease progression, which led to the study not meeting statistical significance. Pfizer Inc PFE.N earlier this month said it would buy Biohaven in a $11.6 billion deal in a bet on the company's commercial migraine drug and other drugs in development. (Reporting by Leroy Leo and Amruta Khandekar in Bengaluru; Editing by Aditya Soni) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.